2020 Business of Personalized Medicine Summit: Break Through to Solutions in the Birthplace of Biotechnology

18 February 2020 Blog
Author(s): Nathan A. Beaver Curt P. Creely Kyle Y. Faget Antoinette F. Konski Judith A. Waltz Emily K. Weber
Published To: Personalized Medicine Bulletin Health Care Law Today

How are businesses across the health care and life sciences spectrum collaborating to capitalize on the commercial promise of personalized medicine? Find out at the 2020 Business of Personalized Medicine Summit — join us at Oyster Point in South San Francisco on Thursday, February 27th!

Since the completion of the Human Genome Project in 2003, the genomic revolution has spurred immeasurable excitement and support surrounding the promise of personalized medicine, setting high expectations for a new era of health care and rapidly transforming the field into a multi-billion dollar industry.

While realizing the medical and commercial potential of personalized medicine has turned out to be neither quick nor easy, we could finally be on the cusp of widespread clinical adoption and improved patient outcomes thanks to recent advances with CRISPR gene editing and targeted therapies as well as the digital transformation of the industry. In fact, in its latest report, Cancer Statistics, 2020, the American Cancer Society cites a 2.2% drop in the U.S. cancer death rate from 2016 to 2017 — the largest single-year drop ever recorded — and attributes it largely to the development of targeted therapies and other personalized medicines for the treatment of lung and skin cancers.

With this welcome news underscoring the real medical contributions of personalized medicine, this year’s Summit aims to explore whether the business community might also be on the verge of capitalizing on the field’s commercial promise and, if so, what that could mean for innovation, investment, profitability, and growth in the space moving forward.

You won’t want to miss these one-of-a-kind discussions with key industry executives in the birthplace of biotechnology — REGISTER TO ATTEND TODAY!

Registration is complimentary for life sciences and health care executives, entrepreneurs, investors, and academics. For more information, visit www.personalizedmedicinesummit.com.

Featured Discussion Topics

 Handshake  The capital raising landscape and lessons learned
 Lightbulb  Spotlight on gene and cell therapy as an innovative and evolving technology area
 DTC Genetic Testing  Capitalizing on the commercial potential of direct-to-consumer genetic testing
 Stethoscope  Strategies for operationalizing a personalized medicine program at the point of care
 Connected Dots  The promise behind AI for discovery, validation, diagnosis, and data sharing
 Companion Diagnostics  Evolving business models for companion diagnostics

Confirmed Speakers

Lisa Alderson
Co-Founder and Chief Executive Officer, Genome Medical, Inc.

Kathleen Barnes, PhD
Director, Colorado Center for Personalized Medicine

Professor and Head, Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus

Paul Billings, MD, PhD
Chief Medical Officer and Senior Vice President, Medical Affairs, Natera

Anita Chawla, PhD
Managing Principal, Analysis Group

Curt Creely
Partner, Foley & Lardner LLP

Nicholas Dracopoli, PhD
Chief Scientific Officer, Delfi Diagnostics

Kyle Faget
Of Counsel, Foley & Lardner LLP

Matt Gardner
Founder and Chief Executive Officer, California Technology Council

Taha Jangda
Partner, HealthX Ventures

Ron Mazumder, PhD, MBA
Vice President and Global Head of Oncology Biomarker Development and Companion Diagnostics, Genentech, Inc.

Christine Meda
Chief Business Officer, IncellDx

Nick Naclerio, PhD
Founding Partner, Illumina Ventures

Jonathan Norris
Managing Director of Sales Origination, Silicon Valley Bank

Ekta Patel, PhD
Head of Pre-Clinical and Translational Sciences, Mustang Bio

Kathryn Phillips, PhD
Founding Director, UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS)

Professor of Health Services Research and Health Economics, Department of Clinical Pharmacy, UCSF School of Pharmacy

Bruce Quinn, MD, PhD
Principal, Bruce Quinn Associates LLC

Robin Smith
Founder and Chief Executive Officer, Orig3n

Judy Waltz
Partner, Foley & Lardner LLP

Emily Weber
Partner, Foley & Lardner LLP

Frank Witney
Operating Partner, Ampersand Capital Partners

About the BPM Summit

Since 2013, Foley & Lardner LLP has collaborated with a multidisciplinary Advisory Board comprised of industry executives to host this one-day thought leadership forum addressing the future of health economics as well as the impact to businesses stemming from personalized medicine’s growing support. The event brings together stakeholders from financial entities, life sciences companies, care providers, and research and policy organizations to discuss critical insights and solutions for product development, commercialization, and mainstream implementation at the point of care.

What Makes the BPM Summit Unique?

Many forums for discussing personalized medicine focus on specialized areas such as underlying technologies, financing, regulatory pathways, or payment issues. The BPM Summit attempts to address cross-sections of such issues with a clear eye towards modeling successful and sustainable business models for entities already engaged in personalized medicine as well as those that seek to enter the space. The BPM Summit aims to set itself apart from other programs by focusing on the business challenges, trends, and opportunities within the personalized medicine marketplace while keeping in mind the potential implications for R&D and healthcare delivery.

Who Should Attend?

Business, legal, and health care professionals interested in industry leaders’ real-world experience on the current state of personalized medicine and where growth and opportunity exist

Business, legal, and health care professionals interested in discussions regarding the regulatory framework for diagnostics and targeted therapies

Executives and entrepreneurs interested in hearing diverse perspectives on both the development and delivery of personalized medicine therapies

Payers interested in the current status and future possibilities regarding reimbursement of personalized medicine technologies

Corporate counsel in life sciences and health care provider organizations

Health care professionals working in the field of personalized medicine

Health care and life sciences investors

Researchers and academic personnel

Non-profit organizations

Register to Attend

To view the complete program agenda, meet the speakers, and register to attend the 2020 Business of Personalized Medicine Summit, please visit www.personalizedmedicinesummit.com. For questions, contact Allison Jones at ajones@foley.com.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services